To serve the Healthy China 2030 initiative and help to arrange the major project of Technological Innovation 2030, we focus on new medicine development caring for serious diseases that threaten the public’s health and other common and frequently-occurring diseases, constantly making contributions to speeding up the establishment of national medical innovation system with Chinese characteristics.
Focuses: innovative chemical medicine, innovative biological medicine, medical equipment and technologies, health service, high-end preparations, etc.
In December 2016, SDIC Venture Capital completed its investment in Eucure (Beijing) Biopharma Co., Ltd (abbreviated as "Eucure Biopharma") with the High-Tech Venture Capital Fund.
Founded in December 2016, Eucure Biopharma is a high-tech enterprise located in Beijing Economic and Technological Development Zone, dedicated to innovative drug research and development. Through the technology platform support from the company's strategic partner, Eucure Biopharma has successfully developed various preclinical antibody products for the R&D of new drugs. At present, Eucure Biopharma's antibody and drug development pipeline is mainly concentrated in the field of cancer treatment. There are already several products that have entered the CMC and are expected to begin to declare clinical trials in 2018. Eucure Biopharma has cooperated with many domestic and foreign pharmaceutical companies in the development of macromolecular drugs including immune checkpoint antibodies, bispecific antibodies, ADC, etc. to find the best treatment for cancer patients.
Through its multi-level and comprehensive value added services after investment, SDIC Venture Capital will assist enterprises in establishing a complete technology and intellectual property system, improving internal management and promoting Eucure Biopharma to become a leader in the research and development of cancer immune drugs.
In December 2017, SDIC Venture Capital accomplished its investment in Chengdu Huajian Pharma Co., Ltd. (hereinafter referred to as HJ Pharma) with National Science and Technology Fund. HJ Pharma focuses on the research and development as well as production of innovative pharmaceutical micromolecule chemicals, which is of great significance to China’s research and development of innovative drugs. With multilevel, all-round value added services after investment, SDIC Venture Capital will help the enterprise establish a complete system of technology and intellectual property and perfect its internal management in hope that HJ Pharma can develop into a leading enterprise in the subdivided industries of biomedicine innovation.
Steered by significant clinical demands and driven by technological innovation, HJ Pharma works on the research and development of innovative drugs with independent intellectual property rights, holding the idea of Chinese wisdom contributing to human health. It’s resolved to become a leading provider of medical blockbusters.
HJ Pharma has established a relatively complete R&D platform which covers drug design, activity evaluation in vitro and in vivo, drug metabolism, synthesis and preparation, quality research, preparations development and pilot magnification. Its product layout is centered on the new generation of tumour micro-environment therapy, the treatment of complex metabolic diseases and other potential significant clinical demands. By now, through independent research and development and introduction, HJ Pharma has formed a development pipeline with great competitiveness and distinct features.
In September, 2016, SDIC Venture Capital completed the investment to Beijing Biocytogen Co., Ltd. (hereinafter referred to as Biocytogen) with High-tech Venture Capital Fund. Biocytogen focuses on gene targeting technologies, products and industrial project applications, fundamentally shoring China's new drugs development. SDIC Venture Capital will assist the enterprise to build a comprehensive technology and IP system, improve inner management and promote Biocytogen to become a great enterprise in innovative biological drugs through multi-layer and all-around post-investment value-added services. After development of almost 8 years, Biocytogen has established a development and service platform of mouse knockout that includes a unique gene targeting vector construction technology with an accurate micro-injection system and high germline transmission efficiency of C57BL/6 mouse embryonic stem cells (ESC). Based on this platform and relying on animal facilities with a combined area of over 10,000 ㎡ at Daxing, Beijing and Haimen, Jiangsu, Biocytogen successfully completed its business transformation from the single service model of preparation of gene engineered animals to the one-stop comprehensive service model of large-scale animal breeding, antibody discovery, and evaluation service of antineoplastic drugs based on Animal Centers. Biocytogen has built a business platform including the development service of genetic editing animal models, large-scale breeding and marketing of animal models, antibody discovery and evaluation service of antineoplastic drugs.
Biocytogen has established a global technical service network which relies on its unique technical platforms, standard operation procedures, strict quality control systems, talented team members, and an efficient executive force. Its customers are from academic institutions such as Harvard University, NIH, Peking University, Tsinghua University, and the Chinese Academy of Sciences. Its clients also include hospitals like Union Hospital, and international companies such as Johnson and Johnson, Roche and other leading pharmaceutical enterprises.
In December 2017, SDIC Venture Capital completed the investment in KBP Biosciences Group (hereinafter referred to as KBP) with its National Science and Technology Fund.
Founded by Dr. Huang Zhenhua, a national expert of "Thousand-Talents Plan", KBP is an international biomedical high-tech enterprise that is devoted to developing original new drugs with independent intellectual property rights to satisfy the huge unmet clinical needs based on innovative research. As a cutting-edge biotech company, KBP specializes in the R&D of innovative medicines for patients with unmet medical needs around the world. Its innovative drug development mindset, independent advantage in pharmaceutical chemistry, and rich clinical development experience and regulatory expertise can help this newcomer find innovative "new chemical entities" (NCEs) for validated targets and bring new hope to the treatment of cardiorenal diseases, infectious diseases, respiratory, inflammatory and autoimmune diseases.
A variety of new drugs under research in KBP has obtained support from national major new drug creation special project. Its leading product under research, KBP-5074, is a mineralocorticoid receptor antagonist, successfully breaking the clinical bottlenecks of existing mineralocorticoid receptor antagonists, is expected to treat cardiovascular diseases. Currently, the Phase II clinical trials of KBP-5074 is underway in the United States. The KBP-7072 is a third-generation aminomethyl tetracycline that is expected to be used in the treatment of multiple drug-resistant bacterial infections. The KBP-7072 has received Fast Track Designations and FDA QIDP certification. It has completed its Phase I trials in the United States and is ready for Phase II. KBP-7026, a CRTH2 antagonist, is expected to treat asthma and COPD.
In December 2017, SDIC Venture Capital accomplished its investment in Hangzhou Lianzhong Medical Science Co., Ltd. (hereinafter referred to as Lianzhong Medical) with National Science and Technology Fund. Lianzhong Medical puts its emphasis on the cross-regional and cross-system platform based on Internet public cloud of medical science, realizing data collection and cloud storage of medical imaging; safe, convenient, and standard transmission of image data; as well as other medical application functions based on cloud storage. Its core product, the medical cloud service platform called “Global Image” has been put into operation in many provinces and cities.
Now, the national health care reform is being further promoted. As a leading company in the field of medical cloud services, Lianzhong Medical plays a significant role in promoting hierarchical diagnosis and treatment; the reform of treating serious diseases without going out of the county and the landing of medical insurance. The Global Image system developed by Lianzhong Medical has solved the problem of resource short in primary hospitals, and has overcome the difficulty of grass-roots patients seeking medical advice. It helps grass-roots patients acquire local high-quality medical resources and services in time and reduces the cost of diagnosis and treatment. Meanwhile, it has established a smooth referral system among upper and lower levels of hospitals, which is of great importance to our society
In December 2017, SDIC Venture Capital accomplished its investment in Beijing Nabai Gen Co., Ltd (hereinafter referred to as NBGen) with Beijing-Tianjin-Hebei Fund. NBGen is an innovator as well as a pioneer in the fields of food safety inspection and animal health in China, providing specialized products and technical services for food safety inspection and prevention, diagnosis and treatment of animal epidemic diseases. As a hi-tech enterprise in Zhongguancun, it has completed the ISO90000 quality system certification.
NBGen was established in 2014 by doctors who had studied abroad and a team with rich experience in product development and marketing. Since the very beginning, it has been providing services for the fields of animal health and biological health with advanced biotechnology, sticking to the management idea of “prevention, diagnosis and treatment”.
In November 2017, SDIC Venture Capital completed the investment in Omni (Suzhou) Pharmaceutical Co., Ltd. (hereinafter referred to as Omni) with its National Science and Technology Fund. Omni is a pharmaceutical company specializing in the R&D and production of respiratory tract drug delivery. Adhering to the tenet of "China manufacture for global sharing", Omni Pharmaceutical Co., Ltd. is committed to breaking the monopoly status of imported pharmaceutical products in the domestic market and providing world-class inhalation preparations. The company was founded in 2011.The R&D center is located in Shanghai Zhangjiang Pharma Valley, and the production base is located in Taicang Biological Industrial Park. Ever since its establishment, Omni has always been supported by internationally renowned investment institutions such as Morningside, Lilly Asia Ventures and KBCP, etc.
Founder Dr. Kai Zhang is a leading expert in the field of respiratory tract drug delivery. He has over 20 years of the R&D and management experience in the field of pharmaceuticals in the United States and China. He has brought several respiratory drug delivery products into the market in the United States. High technical barriers and complex process details make respiratory tract delivery recognized as the industry's high-end preparations. After 6 years of intensive research in the field of respiratory tract administration, Omni has achieved the R&D and production of four mainstream inhalation formulations of powder, aerosol, nasal spray and aerosol, and established a technology platform and production site in line with the international market standard. Among them, the dry powder preparation project has received major national special project support. Furthermore, the company also boasts an independent respiratory device research and development capabilities, which will improve patient compliance into product design. The company's products cover a wide range of respiratory drug delivery in the area, and more than 10 projects under research will enter the clinical research phase this year.
In June, 2017, SDIC Venture Capital contributed with National Science and Technology Fund to lead invest Rongchang Pharmaceuticals,Ltd.,Yantai (hereinafter referred to as RC-Pharma) collaborating with Shenzhen Capital, PAG and Longpan VC. The Major Special Fund will greatly drive RC-Pharma to create the first innovative biological drug for autoimmune diseases and the first antibody-drug conjugate (ADC) antineoplastic in China, gaining new landmark achievements of the industrialization of National Major Scientific and Technological Special Project for “Significant New Drugs Development”.
As an advanced domestic pharmaceutical enterprise covering modern Chinese traditional medicine, innovative biological drug R& D and services, RC-Pharma has undertaken 7 tasks of National Major Scientific and Technological Special Project for “Significant New Drugs Development”. Its technology platform of ADC development so far has the strongest R& D strength in relevant domains in China, whose representative drug, RC-48, has showed the initial effect in Phase I clinical trials, acknowledged as one of the most cutting-edge drugs in China's ADC studies. Meanwhile, RC-Pharma has advanced CDMO service ability in China. It is also the only enterprise that can afford ADC's R& D, manufacture and service, leading the way of the R&D of a number of innovative biological drugs in China.
To lead the investment, SDIC Venture Capital has more ambitions than just promoting RC-Pharma to develop new biological drugs. As the manager of Major Special Fund, through supporting local innovative enterprises in R& D of drugs with a unique development path like RC-Pharma, SDIC Venture Capital hopes to help RC-Pharma perfect its technology platform of new drugs development and modernization of Chinese traditional medicine, constructing an innovative system of R& D of drugs with RC characteristics, ultimately building a first-level pharmaceutical enterprise with international R& D ability and industrial competitiveness.
In December 2017, SDIC Venture Capital completed the investment in Shanghai Zensun Science and Technology Co. Ltd. (hereinafter referred to as Zensun Science and Technology) through National Science and Technology Fund. With this round of investment, the blockbuster of Zensun Science and Technology, rhNRG-1,Neucardin™, can accelerate its process of appearing on China's market and may achieve symbolic achievements of "Significant New Drugs development". rhNRG-1,Neucardin™ is one of the few original innovative drugs which is really developed in China and can access the international market of new drugs. In this round of investment, SDIC Venture Capital intends to provide support for China's world-leading original scientific and technological innovations to reach out to the world and also support the international multi-center clinical trial of the major product of Zensun Science and Technology, so that with its promotion, the rhNRG-1,Neucardin™ can appear on markets both home and abroad as soon as possible.
Zensun Science and Technology is a high-tech biopharmaceutical enterprise driven by the demands of international medical market and based on innovative researches. It focuses on the research and development of original new drugs with independent intellectual property rights. The corporation has two innovative drug research and development platforms focusing on myocardial cell treatment technology and cell energy metabolism treatment technology. It has applied for 186 patents globally and obtained 73 authorizations.
Relying on the myocardial cell treatment technology platform, Zensun Science and Technology has worked on rhNRG-1,Neucardin™ for over a decade, which is the core product used to treat chronic heart failure. This product is literally First-in-Class which not only realizes original innovation but also obtains global patents, rights and interests. It may become a blockbuster. Currently, Zensun Science and Technology has submitted both the ISS and ISE of rhNRG-1,Neucardin™, making clear that the third phase of international multi-center clinical trial of rhNRG-1,Neucardin™ has made big progress.
In addition to this product, the corporation has also discovered that rhNRG-1,Neucardin™ can be used to treat new indications like diastolic heart failure and cerebral stroke. It also developed First-in-Class drugs like rAAV9/cMLCK, which is a gene-based medicine that can be used to treat severe heart failure. Based on the cell energy metabolism treatment platform, the corporation has developed a series of innovative drugs to treat diseases related to senility like functional constipation and Alzheimer disease. The products mentioned above will enter the clinical phase successively in 2018.